Epimmune Inc.

La Jolla Institute for Allergy and Immunology

Cytel Corporation

Pharmexa Inc.

Sandoz Gmbh

Howard M Grey

Alessandro D Sette

John Sidney

Esteban Celis

Scott Southwood

Ralph T Kubo

Robert W Chesnut

Federico C Gaeta

Brian D Livingston

Bjoern Peters

Maria A Vitiello

Robert W Chestnut

Jeffrey L Alexander

Thomas S Arrhenius

Michael Frank Powell

Jeffery L Alexander

Jason Greenbaum

Denise Marie Baker

Carla Oseroff

W Martin Kast

Veronique Schulten

Cecilia Arlehamm

The invention relates to common allergen proteins and peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses of common allergen proteins and peptides. Methods include, for example, modulating an immune response; protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease; and inducing immunological tolerance to the allergen in a subject.

Epitopes from allergen proteins and methods and uses for immune response modulation

The present invention relates toproteins and peptides, and subsequences, portions or modifications thereof and methods and compounds comprising the same for eliciting, stimulating, inducing, promoting, increasing, or enhancing an anti-immune response in a subject.

Antigens and epitopes derived from

The invention relates to Timothy Grass proteins and peptides, subsequences, portions, homologs, variants and derivatives thereof, and methods and uses of Timothy Grass proteins and peptides. Methods include, for example, modulating an immune response; protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease; and inducing immunological tolerance to the allergen in a subject.

Timothy grass allergens and methods and uses for immune response modulation

The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. One such peptide, NMLSTVLGV (SEQ ID NO: 183) is useful to elicit an immune response against influenza. The present invention also provides a heteropolymer of an isolated immunogenic peptide less than 15 amino acids in length comprising the oligopeptide NMLSTVLGV (SEQ ID NO: 183) and at least one different peptide.

HLA binding motifs and peptides and their uses

This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepareepitopes, and to develop epitope-based vaccines directed towards malaria. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of malaria. In particular, this application discloses isolated peptides comprising oligopeptides, for example the oligopeptide GVSENIFLK, or isolated peptides conjugated with T helper peptides that are used as antigens in epitope-based vaccines to prevent and/or treat malaria.

[object Object]

This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.

Inducing cellular immune responses to hepatitis B virus using peptide compositions

This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HPV infection.

Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions

The present invention provides compositions and methods of inhibiting or inducing activation of T cells in a patient. The methods comprise administering a therapeutically effective dose of pharmaceutical compositions comprising a pharmaceutically acceptable carrier and peptides of between about 4 and about 20 residues, that bind antigen binding sites on MHC molecules encoded by substantially all alleles of a DR locus. These peptides are referred to as pan DR binding peptides. The pan DR binding peptides can be used to inhibit immune responses associated with immunopathologies, such as autoimmunity, allograft rejection and allergic responses. The peptides can also be used in combination with CTL peptides to enhance a CTL response.

Alteration of immune response using pan DR-binding peptides

Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions

Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions

Cytotoxic T lymphocyte responses are effectively induced to an antigen of interest, particularly viral, bacterial, parasitic and tumor antigens. Compositions, including pharmaceutical compositions, of CTL-inducing peptide and an adjuvant or a lipidated peptide which induces a helper T cell (HTL) response stimulate the antigen specific CTL response. Among the viral antigens to which the CTL responses are effectively induced in humans are those of hepatitis B. The CTL response may be optimized by a regimen of two or more booster administrations. Cocktails of two or more CTL inducing peptides are employed to optimize epitope and/or MHC class I restricted coverage.

Compositions and methods for eliciting CTL immunity

The present invention provides compositions and methods of inducing immune response in patients. In particular, it provides compositions useful in inducing humoral resposes against desired immunogens, particularly polysaccharides.

Induction of immune response against desired determinants

Methods for making peptides comprising an HLA-A24.1-, HLA-A1-, HLA-A11-, and HLA-A3.2-restricted T cell epitope consisting of about 8-11 amino acid residues, and methods of making a peptide that binds to an HLA-A24.1, HLA-A1, HLA-A11, and HLA-A3.2 molecule at a dissociation constant of less than 500 nM.

Methods for making HLA binding peptides and their uses

Peptide compositions are provided which bind MHC molecules of interest and inhibit T cell activation. The peptide compositions of the present invention comprise various isosteres of naturally occurring amino acid sequences. Such compositions may be used to treat diseases associated with particular DR alleles, including autoimmune diseases such as rheumatoid arthritis.

Growing community of inventors

La Jolla, CA, United States of America

Howard M Grey